In Eli Lilly’s clinical trial program, retatrutide (LY3437943) was administered as a once-weekly subcutaneous injection. Phase 2 trials evaluated maintenance targets of 1 mg, 4 mg, 8 mg, and 12 mg, while Phase 3 trials evaluated 2 mg, 4 mg, 9 mg, and 12 mg. Doses were never initiated at target levels; participants began at 2 mg (or 4 mg) and stepped up every 4 weeks to allow gastrointestinal and cardiac adaptation.
Phase 2 NEJM titration architecture
The foundational human data for retatrutide comes from the 48-week Phase 2 randomized double-blind trial in 338 adults with obesity (NEJM 2023; PMID 37366315).
To evaluate whether slower escalation improved tolerability, researchers tested two distinct starting dose paths for the higher tiers:
- Escalation Scheme A (Slower): Started at 2 mg weekly for 4 weeks, increased to 4 mg for 4 weeks, then 8 mg for 4 weeks, before reaching the 12 mg maintenance ceiling at week 12.
- Escalation Scheme B (Faster): Started directly at 4 mg weekly for 4 weeks, stepped to 8 mg for 4 weeks, and reached 12 mg at week 8.
The results demonstrated that the slower 2 mg starting protocol cut the incidence of severe nausea and vomiting nearly in half compared to the faster 4 mg start, while maintaining identical long-term efficacy.
Phase 2 weight reduction by maintenance dose
Weight loss tracked in a direct, dose-dependent trajectory across 48 weeks:
| Target Dose | Starting Dose | Escalation Steps | Mean Weight Change (24 Wk) | Mean Weight Change (48 Wk) | Discontinuation Rate |
|---|---|---|---|---|---|
| Placebo | — | — | −1.6% | −2.1% | 2.1% |
| 1 mg | 1 mg fixed | No escalation | −7.2% | −8.7% | 6.8% |
| 4 mg | 2 mg | 2 mg → 4 mg | −12.9% | −16.3% | 8.2% |
| 4 mg (fast) | 4 mg fixed | No escalation | −13.5% | −17.3% | 14.0% |
| 8 mg (slow) | 2 mg | 2 mg → 4 mg → 8 mg | −17.3% | −22.8% | 8.8% |
| 8 mg (fast) | 4 mg | 4 mg → 8 mg | −17.9% | −23.9% | 13.1% |
| 12 mg (slow) | 2 mg | 2 mg → 4 mg → 8 mg → 12 mg | −17.5% | −24.2% | 6.0% |
At the top 12 mg dose, 100% of participants lost at least 5% of their body weight, 91% lost at least 10%, 75% lost at least 15%, and 26% achieved ≥30% total body weight reduction.
Phase 3 TRANSCEND program dosing
In the registration Phase 3 program (including TRANSCEND-1, TRANSCEND-T2D-1, and TRANSCEND-CVOT), the dosing architecture was refined into standard 4-week step intervals:
- Weeks 1–4: 2 mg once weekly (initial tolerability evaluation)
- Weeks 5–8: 4 mg once weekly
- Weeks 9–12: 6 mg once weekly (transitional tier in specific cohorts)
- Weeks 13–16: 9 mg once weekly (intermediate maintenance tier)
- Weeks 17+: 12 mg once weekly (maximum target maintenance dose)
This conservative titration prevents the acute transient heart rate spikes observed during rapid glucagon receptor stimulation and stabilizes glycemic levels.
Adverse event patterns during titration
Adverse events in retatrutide trials peaked during the first 1 to 2 weeks of each dose escalation step and steadily diminished as participants remained at a stable maintenance level:
- Gastrointestinal: Nausea (45% at 12 mg), diarrhea (31%), vomiting (20%), and constipation (22%). The majority of events were mild to moderate and resolved with time.
- Cutaneous hyperesthesia: A distinctive sensory adverse effect (increased skin sensitivity or tingling), reported in 7% of participants at higher doses.
- Cardiac chronotropic effects: Mean pulse rate increased by a peak of +4.6 to +9.9 beats per minute around week 24, subsequently declining toward baseline by week 48.
Frequently asked questions
Is retatrutide approved by the FDA?
No. As of 2026, retatrutide remains an investigational compound in Phase 3 development. It does not possess an approved prescribing label from the FDA, EMA, or other major national drug regulators.
Why does retatrutide require titration?
Retatrutide is a triple agonist targeting three receptors: GLP-1, GIP, and glucagon. Starting at a full maintenance dose (e.g. 8 mg or 12 mg) saturates gastric motility and glucagon signaling pathways simultaneously, resulting in severe nausea, acute dehydration, and poor clinical retention.
How does retatrutide dosing compare to tirzepatide?
Tirzepatide (a dual GIP/GLP-1 agonist) titrates from 2.5 mg up to a maximum of 15 mg weekly in 2.5 mg increments. Retatrutide reaches its maximum clinical efficacy at 12 mg weekly, achieving higher percentage weight loss at 12 mg (−24.2%) than tirzepatide did at 15 mg (−20.9% in SURMOUNT-1).
What is retatrutide's terminal half-life?
Retatrutide has an elimination half-life of approximately 6 days in humans, which supports stable once-weekly subcutaneous administration with low peak-to-trough plasma concentration fluctuations.